Scarica l'app Stockscreener
7.47
3.11%
-0.24
Dopo l'orario di chiusura:
7.38
-0.09
-1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Can Vir Biotechnology Inc. stock hit analyst price targetsJuly 2025 Rallies & Low Risk Growth Stock Ideas - mfd.ru
How cyclical is Vir Biotechnology Inc.’s revenue stream2025 Market Sentiment & Technical Pattern Based Signals - mfd.ru
Vir Biotechnology, Inc. (VIR) Stock Analysis: A 111.85% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Is Vir Biotechnology Inc. subject to activist investor interestJuly 2025 Earnings & Weekly High Potential Stock Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - PharmiWeb.com
Vir Biotechnology to unveil Q4 and full year 2025 earnings results - Traders Union
Press Release: Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results - 富途牛牛
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating for VIR with $14 Price Target | VI - GuruFocus
VIR News Today | Why did Vir Biotechnology stock go down today? $VIR - MarketBeat
Vir Biotechnology: The Low-Down On The Readouts Ahead - Seeking Alpha
Vir Biotechnology price target lowered to $24 from $31 at Barclays - TipRanks
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Sato sells $169k in stock By Investing.com - Investing.com Canada
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown - MSN
Vir Biotechnology, Inc. (VIR) Stock Analysis: A Biotech with a Promising 131% Upside Potential - DirectorsTalk Interviews
Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial - Yahoo Finance
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trading Recap: What makes Stran Company Inc Equity Warrant stock attractive today2025 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Update: Can Vir Biotechnology Inc outperform under higher oil pricesJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9%Should You Buy? - MarketBeat
Aug Macro: Can BankUnited Inc outperform under higher oil prices2025 Risk Factors & Daily Market Momentum Tracking - baoquankhu1.vn
Aug Final Week: Is Vir Biotechnology Inc a strong growth stock2025 Investor Takeaways & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (NASDAQ:VIR) Top 10 Nasdaq Stocks Spotlight on Research - Kalkine Media
Vir Biotechnology (VIR) Advances in Hepatitis Delta Treatment - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Trading 7.3% HigherWhat's Next? - MarketBeat
Vir Biotechnology shows positive results in hepatitis delta trial - Traders Union
Vir Biotechnology (VIR) Reports Positive Trial Results in Hepati - GuruFocus
Vir Biotechnology reports promising results for hepatitis delta therapy By Investing.com - Investing.com Nigeria
Vir Biotechnology reports promising results for hepatitis delta therapy - Investing.com
Vir Biotechnology reports positive Phase 2 hepatitis delta data, outlines 2026 clinical milestones - MSN
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - BioSpace
Vir Biotechnology advances hepatitis delta program and cash runway - TipRanks
Vir Biotechnology provides updates on chronic hepatitis Delta and oncology programs and upcoming 2026 clinical milestones - marketscreener.com
Vir Biotechnology reports positive hepatitis delta trial data - StreetInsider
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones - TradingView — Track All Markets
How Vir Biotechnology Inc. stock performs after earnings2025 Biggest Moves & Verified Momentum Stock Watchlist - ulpravda.ru
Is Vir Biotechnology Inc. stock a safe haven assetWeekly Profit Analysis & Weekly Stock Breakout Alerts - Улправда
Will Vir Biotechnology Inc. stock keep outperforming rivalsJuly 2025 Big Picture & Low Risk Investment Opportunities - Улправда
Profit Recap: Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Summary Report & Free High Accuracy Swing Entry Alerts - Улправда
Bank of America Securities Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - Bộ Nội Vụ
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):